Key Abstracts in Myasthenia Gravis From AANEM 2026

20 Oct 2026 0 comments

Myasthenia gravis highlights from AANEM 2026 include rituximab timing in MuSK-MG; benefit from gefurulimab, telitacicept, and efgartigimod; and results from re-treatment with Descartes-08.
Medscape

Source: Medscape Neurology Published 19 Oct 2026 Imported 20 Oct 2026 Relevancy: Not reviewed

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment